NCT03388853View on ClinicalTrials.gov

Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD.

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

December 21, 2019

Study Completion Date

December 21, 2019

Conditions

COPD

Interventions

DRUG

Acetylcysteine/Doxofylline

Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.

OTHER

Placebo

Placebo once daily for four weeks.

Trial Locations (2)

Unknown

Cukurova University Faculty of Medicine, Chest Diseases Department, Adana

Health Sciences University, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul

All Listed Sponsors

lead

Neutec Ar-Ge San ve Tic A.Ş

INDUSTRY

NCT03388853 - Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD. | Biotech Hunter | Biotech Hunter